Investors must look beyond headline ARR figures from YC companies. High-growth numbers are often calculated by annualizing a single month's revenue, which can be misleadingly inflated by non-recurring, one-time hardware sales rather than sticky, subscription-based software revenue.

Founders should avoid sharing a standard set of metrics during fundraising. This preserves flexibility, allowing them to highlight whichever metric looks best at that moment, rather than being committed to a single indicator that may stall and kill the deal.

Lin warns that much of today's AI revenue is 'experimental,' where customers test solutions without long-term commitment. He calls annualizing this pilot revenue 'a joke.' He advises founders to prioritize slower, high-quality, high-retention revenue over fast, low-quality growth that will eventually churn.

Investors and acquirers pay premiums for predictable revenue, which comes from retaining and upselling existing customers. This "expansion revenue" is a far greater value multiplier than simply acquiring new customers, a metric most founders wrongly prioritize.

With Seed-to-A conversion below 20%, VCs are intensely vetting revenue quality. They are wary of "vibe ARR" inflated by pilots, credits, or non-recurring fees. Founders must demonstrate true, sticky recurring revenue with high customer loyalty and switching costs to secure a Series A.

AI startups can show explosive growth, like reaching millions in ARR in months, before any customers have renewed. This makes traditional traction analysis difficult for VCs, who must underwrite deals at high valuations based on uncertain, potentially ephemeral, customer signals.

Gokul Rajaram asserts that ARR (Annual Recurring Revenue) multiples are a vanity metric divorced from market realities. He advises founders and investors to instead prioritize capital efficiency, focusing on the burn multiple (cost to acquire $1 of revenue) and Net Revenue Retention (NRR) as the true indicators of a healthy business.

Beyond outright fraud, startups often misrepresent financial health in subtle ways. Common examples include classifying trial revenue as ARR or recognizing contracts that have "out for convenience" clauses. These gray-area distinctions can drastically inflate a company's perceived stability and mislead investors.

Tranched rounds involve an investor buying shares at two prices (e.g., $250M and $1B) in the same financing. While the investor gets a lower blended cost basis, the company gets to announce the higher valuation. It's a financial engineering tactic that satisfies egos but creates an optics trap.